Keshelava N - Search Results

1

Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.

Keshelava N, Groshen S, Reynolds CP. Keshelava N, et al. Cancer Chemother Pharmacol. 2000;45(1):1-8. doi: 10.1007/PL00006736. Cancer Chemother Pharmacol. 2000. PMID: 10647494

2

Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.

Yang B, Keshelava N, Anderson CP, Reynolds CP. Yang B, et al. Among authors: keshelava n. Cancer Res. 2003 Apr 1;63(7):1520-6. Cancer Res. 2003. PMID: 12670899

3

Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53.

Keshelava N, Tsao-Wei D, Reynolds CP. Keshelava N, et al. Clin Cancer Res. 2003 Aug 15;9(9):3492-502. Clin Cancer Res. 2003. PMID: 12960142

4

Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.

Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Keshelava N, et al. J Natl Cancer Inst. 2007 Jul 18;99(14):1107-19. doi: 10.1093/jnci/djm044. Epub 2007 Jul 10. J Natl Cancer Inst. 2007. PMID: 17623797

5

Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.

Keshelava N, Seeger RC, Reynolds CP. Keshelava N, et al. Eur J Cancer. 1997 Oct;33(12):2002-6. doi: 10.1016/s0959-8049(97)00213-x. Eur J Cancer. 1997. PMID: 9516842

6

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.

Keshelava N, Seeger RC, Groshen S, Reynolds CP. Keshelava N, et al. Cancer Res. 1998 Dec 1;58(23):5396-405. Cancer Res. 1998. PMID: 9850071

7

p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.

Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP. Keshelava N, et al. Med Pediatr Oncol. 2000 Dec;35(6):563-8. doi: 10.1002/1096-911x(20001201)35:6<563::aid-mpo15>3.0.co;2-j. Med Pediatr Oncol. 2000. PMID: 11107118

8

Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.

Goto H, Keshelava N, Matthay KK, Lukens JN, Gerbing RB, Stram DO, Seeger RC, Reynolds CP. Goto H, et al. Among authors: keshelava n. Med Pediatr Oncol. 2000 Dec;35(6):619-22. doi: 10.1002/1096-911x(20001201)35:6<619::aid-mpo28>3.0.co;2-h. Med Pediatr Oncol. 2000. PMID: 11107131

9

Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.

Anderson CP, Keshelava N, Satake N, Meek WH, Reynolds CP. Anderson CP, et al. Among authors: keshelava n. Med Pediatr Oncol. 2000 Dec;35(6):659-62. doi: 10.1002/1096-911x(20001201)35:6<659::aid-mpo38>3.0.co;2-4. Med Pediatr Oncol. 2000. PMID: 11107141

10

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.

Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP. Keshelava N, et al. Cancer Res. 2001 Aug 15;61(16):6185-93. Cancer Res. 2001. PMID: 11507071

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters